N. Botwood

645 total citations
19 papers, 525 citations indexed

About

N. Botwood is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, N. Botwood has authored 19 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 4 papers in Surgery. Recurrent topics in N. Botwood's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (4 papers). N. Botwood is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (4 papers). N. Botwood collaborates with scholars based in United Kingdom, United States and Ireland. N. Botwood's co-authors include Alex Y. Chang, Nick Thatcher, Reury-Perng Perng, Claire Watkins, Chao‐Jung Tsao, Purvish M. Parikh, Eng Huat Tan, Sumitra Thongprasert, James Chih‐Hsin Yang and C. Lowdell and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

N. Botwood

19 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Botwood United Kingdom 10 337 314 122 90 62 19 525
Alessandro Bertolini Italy 11 515 1.5× 532 1.7× 124 1.0× 103 1.1× 17 0.3× 22 760
Rocco De Vivo Italy 14 166 0.5× 172 0.5× 78 0.6× 109 1.2× 30 0.5× 27 429
Riccardo Ricotta Italy 13 307 0.9× 192 0.6× 165 1.4× 25 0.3× 34 0.5× 37 511
M. Lomas Spain 7 419 1.2× 364 1.2× 94 0.8× 42 0.5× 9 0.1× 23 518
Miah Hiang Tay Singapore 11 157 0.5× 207 0.7× 112 0.9× 59 0.7× 12 0.2× 23 437
J McKendrick Australia 9 338 1.0× 180 0.6× 121 1.0× 81 0.9× 39 0.6× 24 525
Carlo Barone Italy 13 210 0.6× 200 0.6× 66 0.5× 66 0.7× 14 0.2× 20 394
E Piana Italy 11 390 1.2× 340 1.1× 67 0.5× 109 1.2× 16 0.3× 28 592
Yong Mun United States 11 313 0.9× 115 0.4× 132 1.1× 57 0.6× 14 0.2× 43 464
E. Mickiewicz Argentina 9 372 1.1× 166 0.5× 72 0.6× 99 1.1× 28 0.5× 15 639

Countries citing papers authored by N. Botwood

Since Specialization
Citations

This map shows the geographic impact of N. Botwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Botwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Botwood more than expected).

Fields of papers citing papers by N. Botwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Botwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Botwood. The network helps show where N. Botwood may publish in the future.

Co-authorship network of co-authors of N. Botwood

This figure shows the co-authorship network connecting the top 25 collaborators of N. Botwood. A scholar is included among the top collaborators of N. Botwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Botwood. N. Botwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Robertson, Jane, N. Botwood, Mace L. Rothenberg, & Hans‐Joachim Schmoll. (2009). Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III. Clinical Colorectal Cancer. 8(1). 59–60. 39 indexed citations
2.
Chau, Ian, David Cunningham, Tamas Hickish, et al.. (2007). Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Annals of Oncology. 18(4). 730–737. 31 indexed citations
3.
O’Byrne, Kenneth J., Sarah Danson, David J. Dunlop, et al.. (2007). Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(22). 3266–3273. 42 indexed citations
4.
Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855. 144 indexed citations
5.
Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855. 106 indexed citations
6.
Chau, Ian, et al.. (2004). Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3572–3572. 10 indexed citations
7.
O’Byrne, Kenneth J., L. Clarke, David J. Dunlop, et al.. (2004). Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7101–7101. 2 indexed citations
8.
O’Byrne, Kenneth J., L. Clarke, David J. Dunlop, et al.. (2004). Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7101–7101. 1 indexed citations
9.
Chau, Ian, et al.. (2004). Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3572–3572. 7 indexed citations
10.
James, R.D., N. Botwood, C. C. Vernon, & P. Price. (2003). Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: A phase I study. Annals of Oncology. 14(4). 570–573. 5 indexed citations
11.
Lees, Michael, et al.. (2003). Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. The European Journal of Health Economics. 4(3). 216–221. 12 indexed citations
12.
Aristides, M, et al.. (2002). Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer. PharmacoEconomics. 20(5). 325–337. 34 indexed citations
13.
Botwood, N., J McKendrick, M Aristides, et al.. (2001). Economic evaluation of Gemzar/cisplatin relative to other cisplatin based treatments for non small cell lung (NSCLC) cancer in the UK. European Journal of Cancer. 37. S233–S233. 1 indexed citations
14.
Botwood, N., J McKendrick, M Aristides, et al.. (2001). CN4: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK. Value in Health. 4(2). 54–55. 1 indexed citations
15.
16.
Aristides, M, N. Botwood, J McKendrick, et al.. (2001). PCN9: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK. Value in Health. 4(2). 87–87. 1 indexed citations
17.
Botwood, N., R.D. James, C. C. Vernon, & P. Price. (2000). Raltitrexed (‘Tomudex’) and radiotherapy can be combined as postoperative treatment for rectal cancer. Annals of Oncology. 11(8). 1023–1028. 20 indexed citations
18.
Botwood, N., C. Lewanski, & C. Lowdell. (1999). The risks of treating keloids with radiotherapy.. British Journal of Radiology. 72(864). 1222–1224. 63 indexed citations
19.
Botwood, N., et al.. (1999). Bilateral Cerebellopontine Metastases in a Patient with an Unknown Primary. Clinical Oncology. 11(4). 272–273. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Bertolini Breakdown of academic impact, for papers by Rocco De Vivo Breakdown of academic impact, for papers by Riccardo Ricotta Breakdown of academic impact, for papers by M. Lomas Breakdown of academic impact, for papers by Miah Hiang Tay Breakdown of academic impact, for papers by J McKendrick Breakdown of academic impact, for papers by Carlo Barone Breakdown of academic impact, for papers by E Piana Breakdown of academic impact, for papers by Yong Mun Breakdown of academic impact, for papers by E. Mickiewicz
Rankless by CCL
2026